We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®

News   Feb 17, 2010

 
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
 
 
Advertisement
 

RELATED ARTICLES

Drug That Targets Challenging Cancer Mutation Could Treat Several Tumor Types

News

A new clinical trial shows a novel drug designed to counter the effects of an important cancer mutation could be effective against a range of tumor types including lung and gynecological cancers.

READ MORE

Avoiding Side Effects Associated With Cancer Treatment

News

Researchers at the University of California, Irvine and Switzerland's Lausanne University Hospital/University of Lausanne (CHUV/UNIL) may have found a way to treat cancer without the onset of debilitating side effects.

READ MORE

Spanish Study Explores Vitamin D Deficiency in COVID-19 Patients

News

Over 80 percent of 200 COVID-19 patients in a hospital in Spain have vitamin D deficiency, according to a new study.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE